Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — FY2019 Earnings Presentation
28 slides from Vivoryon Therapeutics's earnings presentation, Mar 26, 2020
Slide 1: The 2019 Full Year Results & Outlook 2020
THE 2019 FULL YEAR RESULTS & OUTLOOK 2020 Halle (Saale)/Munich, March 26, 2020 | Vivoryon Therapeutics AG
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on,
Slide 3: Welcome to Vivoryon Therapeutics
WELCOME TO VIVORYON THERAPEUTICS - TODAY ON THE CALL - Dr. Ulrich Dauer Dr. Michael Schaeffer Chief Executive Officer Chief Business Officer © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 3
Slide 4: Agenda
01 HIGHLIGHTS IN 2019 02 PORTFOLIO AGENDA 03 FINANCIALS 2019 04 OUTLOOK 05 Q&A © Vivoryon Therapeutics AG FY 2019 – March 26, 2020
Slide 5: 01 Highlights in 2019
01 HIGHLIGHTS IN 2019
Slide 6: Highlights 2019
HIGHLIGHTS 2019 Highlights § NIH grant awarded of 15 mill USD § Successful capital increases with new strategic investors in April with 8.2 mill. EUR and in October 43 mill. EUR § Probiodrug AG becoming Vivoryon Therapeutics AG § Option Agreement with MorphoSys AG Post-Period § Nordic Bioscience and
Slide 7: 02 Portfolio
02 PORTFOLIO
Slide 8: Growth Trajectory Beyond AD
GROWTH TRAJECTORY BEYOND AD ▪ Building on strong safety package and Phase 2b ready first sign of improvement of cognition lead asset in ▪ Well-informed Phase 2b trial could lead Alzheimer’s disease to results in 2022 in Europe and What if all of us get a chance to age healthy…? potential conditional
Slide 9: Alzheimer's Represents the Largest Unmet Medical Need in Healthcare
ALZHEIMER’S REPRESENTS THE LARGEST UNMET MEDICAL NEED IN HEALTHCARE 11% of elderly is estimated to Global AD healthcare costs are 4 Only Alzheimer’s drugs are get Alzheimer’s ~$1 trillion/year approved, which are only treating symptoms $290bn total cost There are 50m AD patients estimation in 2019 o
Slide 10: PQ912 a First-in-Class QPCT Inhibitor Targeting Cognition
PQ912 A FIRST-IN-CLASS QPCT Toxic pGlu species drive multiple AD-associated pathways, INHIBITOR TARGETING COGNITION including oligomer aggregation, neuro-inflammation and tau-mediated neurotoxicity © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 10
Slide 11: A European Phase 2b Study in AD
A EUROPEAN PHASE 2B STUDY IN AD Advancing disease modifying treatment and non-invasive diagnostics of Alzheimers disease Phase 2b design Objectives Exploratory Endpoints § Multicenter (10 sites) § Primary: § Cognition by DSTT § Randomized, double-blind, placebo- § Safety for Dose Selection § Languag
Slide 12: US Phase 2b
US PHASE 2B Phase 2b design with similar endpoints NIH grant of USD 15m supports US trial • Randomized placebo controlled • Dose escalation up to 600 mg • MMSE 20-30 • CSF amyloid positive • Primary endpoint: cognitive function Parameter US Phase 2b has a treatment duration of 78 weeks Principal inv
Slide 13: Partner MorphoSys Will Drive Oncology
PARTNER MORPHOSYS WILL DRIVE ONCOLOGY Exclusive option agreement on PQ912 and QPCTL platform in oncology EUR 15m commitment in the ongoing rights issue: • Commitment in the rights issue of up to EUR 15m, regardless of option exercise • Acquisition of exclusive option to license QPCTL inhibitors for
Slide 14: Vivoryon's Glutaminyl Cyclase Platform Is Uniquely Positioned in Immuno-Oncology
VIVORYON’S GLUTAMINYL CYCLASE PLATFORM IS UNIQUELY POSITIONED IN IMMUNO-ONCOLOGY Glutaminyl cyclase inhibitors have beneficial properties for IO PQ912 blocks tumor escape and resensitizes tumors Vivoryon owns first-in-class QPCTL small molecule inhibitor ▪ Tumor cells use expression platform: of “do
Slide 15: Differentiated Mode of Action of QPCTL Inhibitors in Oncology
DIFFERENTIATED MODE OF ACTION OF QPCTL INHIBITORS IN ONCOLOGY © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 15
Slide 16: Vivoryon's First-in-Class Drug Pipeline
VIVORYON’S FIRST-IN-CLASS DRUG PIPELINE © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 16
Slide 17: 03 Financials 2019
OD a © N Y | <x O z= < Zz i a8) ©
Slide 18: Capital Increase
CAPITAL INCREASE © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 18
Slide 19: Shareholders and Stock
SHAREHOLDERS AND STOCK Shareholder structure1 Stock Share Price ISIN: DE0007921835 WKN: 792183 Ticker symbol: VVY Types of shares: Bearer shares Number of shares 19,975,482 Euronext Amsterdam / Stock exchange: Xetra Frankfurt Liquidity provider: Kempen & Co. Listing agent: Kempen & Co. First trading
Slide 20: Key Financial Highlights (P&L): According to IFRS
KEY FINANCIAL HIGHLIGHTS (P&L): ACCORDING TO IFRS IN €k 2019 2018 % Research and development expenses -4,751 -4,836 -1,8 General and administrative expenses -3,023 -2,891 4,6 Other operating income 59 29 103,4 Operating loss -7,715 -7,698 0,2 Finance income 0 2 - Finance expenses -108 -41 163,4 Net
Slide 21: Key Financial Figures (According to IFRS)
KEY FINANCIAL FIGURES (ACCORDING TO IFRS) In €k Dec 31, 2019 Dec 31, 2018 Earnings, Financial and Net Assets Position Operating loss -7,715 -7,698 Finance income/loss -108 -39 Net loss for the period -7,823 -7,737 Equity (end of the year) 42,665 1,230 Equity ratio (end of the year) (in %) 93,0 30.4
Slide 22: 04 Outlook
“X) 04 OUTLOOK
Slide 23: Near Term News Flow Coming from PQ912
NEAR TERM NEWS FLOW COMING FROM PQ912 PQ912 First Completed Completed Results and patient recruitment patient application for Potential conditional approval in AD Phase 2b EU (n=250) follow-up conditional approval First Completed Completed Results Patient recruitment patient Phase 2b Phase 2b US (n=
Slide 24: Outlook
OUTLOOK First Patient in VIVIAD 2 IND-Filing for PQ912 0 Exploit potential of unique patent estate for QPCT/L 2 inhibitors in immune oncology 0 Adding robustness to our R&D pipeline Please note: timing of news flow is indicative © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 24
Slide 25: Outlook
OUTLOOK Mid-term focus of Vivoryon Therapeutics´ business activities ¡ Execution of the Phase 2b clinical study program for PQ912. ¡ Development of PQ912 and other QPCTL inhibitors in oncology. ¡ Further scientific analysis of potential indications for the use of QPCT/L inhibitors. ¡ Additional lice
Slide 26: Financial Calendar 2020
FINANCIAL CALENDAR 2020 Please note: Subject to change, for actual information please see Homepage © Vivoryon Therapeutics AG FY 2019 – March 26, 2020 26
Slide 27: Q&A
05 Q&A
Slide 28: www.vivoryon.com
www.vivoryon.com Halle (Saale) Munich Weinbergweg 22 Franz-Josef-Delonge-Str. 5 06120 Halle (Saale) 81249 München Germany Germany info@vivoryon.com +49 (0)345 555 99 00